Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
MALE
Healthy Volunteers
NCT07506369

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Led by University Hospital, Gentofte, Copenhagen · Updated on 2026-04-01

18

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.

CONDITIONS

Official Title

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Who Can Participate

Age: 18Years - 65Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male
  • Age between 18 and 65 years at the time of inclusion
  • Body mass index 18-27 kg/m2
  • Fat percentage < 20%
  • Informed oral and written consent
Not Eligible

You will not qualify if you...

  • Anaemia (haemoglobin below normal range)
  • History of hepatobiliary and/or gastrointestinal disorder(s)
  • Kidney disease
  • Previous gastric or intestinal resection, cholecystectomy and/or any major intra-abdominal surgery (including bariatric surgery)
  • Previous pancreatic disease and/or neoplasia
  • Regular tobacco smoking and/or use of other nicotine products
  • Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
  • Initiation of special diets, lifestyle changes and/or weight loss >5% of total body weight within three months prior to or during study period
  • Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Center for Clinical Metabolic Research, Gentofte Hospital

Hellerup, Capital Region, Denmark, 2900

Actively Recruiting

Loading map...

Research Team

A

Andreas H Lange

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here